Literature DB >> 29468507

Impact of clinical factors and UGT1A9 and CYP2B6 genotype on inter-individual differences in propofol pharmacokinetics.

Akihiro Kanaya1, Toshihiro Sato2, Nobuo Fuse3, Hiroaki Yamaguchi2, Nariyasu Mano2, Masanori Yamauchi4.   

Abstract

PURPOSE: Propofol is one of the most widely used fast-acting intravenously administered anesthetics. However, although large inter-individual differences in dose requirements and recovery time have been observed, there are few previous studies in which the association between several potential covariates, including genetic factors such as the UGT1A9 and CYP2B6 genotypes, and propofol pharmacokinetics was simultaneously examined. This study aimed to identify factors determining propofol pharmacokinetics.
METHODS: Eighty-three patients were enrolled, and their blood samples were collected 1, 5, 10, and 15 min after administering a single intravenous bolus of propofol at a dose of 2.0 ml/kg to measure propofol plasma concentration. Area under the time-plasma concentration curve from zero up to the last measurable time point (AUC15min) was determined from the concentration data. The inter-individual variability of the propofol pharmacokinetics was evaluated by investigating relationships between AUC15min and genotype of UGT1A9 and CYP2B6; clinical factors, such as age, sex, body mass index (BMI), and preoperative hematological examination; and hemodynamic variables measured by a pulse dye densitogram analyzer. The Spearman rank correlation coefficient and the Mann-Whitney U test were used for the statistical analysis of continuous and categorical values, respectively. Subsequently, clinical factors that had p values of < 0.05 in the univariate analysis were examined in a multivariate analysis using multiple linear regression analysis.
RESULTS: Age, BMI, indocyanine green disappearance ratio (K-ICG), hepatic blood flow (HBF), preoperative hemoglobin level, and sex were correlated with AUC15min (p < 0.05) in univariate analysis. Multivariate analysis performed to adjust for age, BMI, K-ICG, HBF, preoperative hemoglobin level, and sex revealed only BMI as an independent factor associated with AUC15min.
CONCLUSIONS: This study demonstrated that BMI influences propofol pharmacokinetics after its administration as a single intravenous injection, while UGT1A9 and CYP2B6 SNPs, other clinical factors, and hemodynamic variables do not. These results suggest that BMI is an independent factor associated with propofol pharmacokinetics in several potential covariates. CLINICAL TRIALS REGISTRATION NUMBER: University Hospital Medical Information Network (UMIN000022948).

Entities:  

Keywords:  Body mass index; CYP2B6; Pharmacokinetics; Propofol; Single-nucleotide polymorphism; UGT1A9

Mesh:

Substances:

Year:  2018        PMID: 29468507     DOI: 10.1007/s00540-018-2470-3

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  31 in total

Review 1.  Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.

Authors:  A A Mangoni; S H D Jackson
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

2.  Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia.

Authors:  Irena Loryan; Marja Lindqvist; Inger Johansson; Masahiro Hiratsuka; Ilse van der Heiden; Ron H N van Schaik; Jan Jakobsson; Magnus Ingelman-Sundberg
Journal:  Eur J Clin Pharmacol       Date:  2011-10-18       Impact factor: 2.953

3.  Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population.

Authors:  Masahiro Hiratsuka; Yoh Takekuma; Naomi Endo; Kaori Narahara; Samar Ismail Hamdy; Yukinaga Kishikawa; Masaki Matsuura; Yasuyuki Agatsuma; Tomoko Inoue; Michinao Mizugaki
Journal:  Eur J Clin Pharmacol       Date:  2002-08-14       Impact factor: 2.953

4.  A Case of Delayed Emergence After Propofol Anesthesia: Genetic Analysis.

Authors:  Hiroshi Yonekura; Norie Murayama; Hiroshi Yamazaki; Kazuya Sobue
Journal:  A A Case Rep       Date:  2016-12-01

5.  Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes.

Authors:  M H Court; S X Duan; L M Hesse; K Venkatakrishnan; D J Greenblatt
Journal:  Anesthesiology       Date:  2001-01       Impact factor: 7.892

6.  The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.

Authors:  Hugo Girard; Lyne Villeneuve; Michael H Court; Louis-Charles Fortier; Patrick Caron; Qin Hao; Lisa L von Moltke; David J Greenblatt; Chantal Guillemette
Journal:  Drug Metab Dispos       Date:  2006-04-04       Impact factor: 3.922

7.  Bispectral index, serum drug concentrations and emergence associated with individually adjusted target-controlled infusions of remifentanil and propofol for laparoscopic surgery.

Authors:  S C Hoymork; J Raeder; B Grimsmo; P A Steen
Journal:  Br J Anaesth       Date:  2003-12       Impact factor: 9.166

8.  Women emerge from general anesthesia with propofol/alfentanil/nitrous oxide faster than men.

Authors:  T J Gan; P S Glass; J Sigl; P Sebel; F Payne; C Rosow; P Embree
Journal:  Anesthesiology       Date:  1999-05       Impact factor: 7.892

9.  A general purpose pharmacokinetic model for propofol.

Authors:  Douglas J Eleveld; Johannes H Proost; Luis I Cortínez; Anthony R Absalom; Michel M R F Struys
Journal:  Anesth Analg       Date:  2014-06       Impact factor: 5.108

10.  Pharmacology of an emulsion formulation of ICI 35 868.

Authors:  J B Glen; S C Hunter
Journal:  Br J Anaesth       Date:  1984-06       Impact factor: 9.166

View more
  3 in total

1.  Effect of sex and polymorphisms of CYP2B6 and UGT1A9 on the difference between the target-controlled infusion predicted and measured plasma propofol concentration.

Authors:  Ai Fujita; Kengo Hayamizu; Tatsuya Yoshihara; Masayoshi Zaitsu; Fumie Shiraishi; Hisatomi Arima; Kazumasa Matsuo; Kanako Shiokawa; Hidekazu Setoguchi; Toshiyuki Sasaguri
Journal:  JA Clin Rep       Date:  2018-08-13

2.  GABRA1 and GABRB2 Polymorphisms are Associated with Propofol Susceptibility.

Authors:  Youjie Zeng; Si Cao; Minghua Chen; Chao Fang; Wen Ouyang
Journal:  Pharmgenomics Pers Med       Date:  2022-02-09

Review 3.  Clinical Importance of Potential Genetic Determinants Affecting Propofol Pharmacokinetics and Pharmacodynamics.

Authors:  Ivana Budic; Tatjana Jevtovic Stoimenov; Dimitrije Pavlovic; Vesna Marjanovic; Ivona Djordjevic; Marija Stevic; Dusica Simic
Journal:  Front Med (Lausanne)       Date:  2022-02-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.